Curcumin And/or Omega-3 Polyunsaturated Fatty Acids Supplementation Reduces Insulin Resistance and Blood Lipids in Individuals with High Risk of Type 2 Diabetes: a Randomised Controlled Trial

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2019 Jan 28

PMID 30684965

Citations 44

Authors

Rohith N Thota

Shamasunder H Acharya

Manohar L Garg

Affiliations

Soon will be listed here.

Abstract

Background: Lowering insulin resistance and dyslipidaemia may not only enhance glycaemic control but also preserve the β-cell function, reducing the overall risk of developing type 2 diabetes (T2D). The current study was aimed to evaluate the effects of curcumin and/or long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) supplementation on glycaemic control and blood lipid levels in individuals at high risk of developing T2D.

Methods: This was a 2 × 2 factorial, randomised, double-blinded, placebo-controlled study. Participants were allocated to either double placebo (PL) or curcumin plus placebo matching for LCn-3PUFA (CC), or LCn-3PUFA plus placebo matching for curcumin (FO), or curcumin plus LCn-3PUFA (CC-FO) for twelve weeks. Primary outcome of the trial was glycaemic indices (HbA1C, fasting glucose and insulin). Insulin resistance and sensitivity is measured using homeostatic model assessment model.

Results: A total of sixty-four participants (PL, n = 16; CC, n = 15; FO, n = 17, CC-FO, n = 16) were included in the final analysis. Post-intervention, HbA1c and fasting glucose remained unchanged across all the groups. Insulin sensitivity was significantly improved in the CC supplemented group (32.7 ± 10.3%) compared to PL (P = 0.009). FO and CC-FO tended to improve insulin sensitivity by 14.6 ± 8.5% and 8.8 ± 7.7% respectively, but the difference did not reach significance. Triglyceride levels were further increased in the PL (26.9 ± 7.4%), however, CC and CC-FO supplementation reduced the triglycerides, FO resulted in the greatest reduction in triglycerides (- 16.4 ± 4.5%, P < 0.001).

Conclusion: Reduction in insulin resistance and triglycerides by curcumin and LCn-3PUFA appears to be attractive strategies for lowering the risk of developing T2D. However, this study failed to demonstrate complimentary benefits of curcumin and LCn-3PUFA on glycaemic control.

Trail Registration: ACTRN12615000559516 .

Citing Articles

Nutraceuticals and Supplements in Management of Prediabetes and Diabetes.

Derosa G, DAngelo A, Angelini F, Belli L, Cicero A, Da Ros R Nutrients. 2025; 17(1.

PMID: 39796448 PMC: 11723399. DOI: 10.3390/nu17010014.

Alzheimer's Disease, Obesity, and Type 2 Diabetes: Focus on Common Neuroglial Dysfunctions (Critical Review and New Data on Human Brain and Models).

Toledano A, Rodriguez-Casado A, Alvarez M, Toledano-Diaz A Brain Sci. 2024; 14(11).

PMID: 39595866 PMC: 11591712. DOI: 10.3390/brainsci14111101.

Overview of anti-inflammatory diets and their promising effects on non-communicable diseases.

Yu X, Pu H, Voss M Br J Nutr. 2024; 132(7):898-918.

PMID: 39411832 PMC: 11576095. DOI: 10.1017/S0007114524001405.

Decoding potential targets and pharmacologic mechanisms of curcumin in treating non-small cell lung carcinoma via bioinformatics and molecular docking.

Li J, Zhang Z, Zhao J, Liu S, Feng C, Deng H Braz J Med Biol Res. 2024; 57:e13550.

PMID: 39258670 PMC: 11379430. DOI: 10.1590/1414-431X2024e13550.

Curcumin: A Golden Approach to Healthy Aging: A Systematic Review of the Evidence.

Nunes Y, Mendes N, de Lima E, Chehadi A, Lamas C, Haber J Nutrients. 2024; 16(16).

PMID: 39203857 PMC: 11357524. DOI: 10.3390/nu16162721.

References

Saltiel A, Kahn C . Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001; 414(6865):799-806. DOI: 10.1038/414799a. View

Martin B, Warram J, Krolewski A, Bergman R, Soeldner J, Kahn C . Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 1992; 340(8825):925-9. DOI: 10.1016/0140-6736(92)92814-v. View

Frohlich J, Dobiasova M . Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem. 2003; 49(11):1873-80. DOI: 10.1373/clinchem.2003.022558. View

Black S, Kushner I, Samols D . C-reactive Protein. J Biol Chem. 2004; 279(47):48487-90. DOI: 10.1074/jbc.R400025200. View

De Caterina R, Madonna R, Bertolotto A, Schmidt E . n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. Diabetes Care. 2007; 30(4):1012-26. DOI: 10.2337/dc06-1332. View

Weisberg S, Leibel R, Tortoriello D . Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology. 2008; 149(7):3549-58. PMC: 2453081. DOI: 10.1210/en.2008-0262. View

Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R . Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care. 2008; 32(2):361-6. PMC: 2628708. DOI: 10.2337/dc08-0854. View

Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens R, Kern P . Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab. 2008; 296(3):E480-9. PMC: 2660148. DOI: 10.1152/ajpendo.90892.2008. View

Tabak A, Jokela M, Akbaraly T, Brunner E, Kivimaki M, Witte D . Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009; 373(9682):2215-21. PMC: 2726723. DOI: 10.1016/S0140-6736(09)60619-X. View

10.

Kim T, Davis J, Zhang A, He X, Mathews S . Curcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cells. Biochem Biophys Res Commun. 2009; 388(2):377-82. DOI: 10.1016/j.bbrc.2009.08.018. View

11.

Na L, Zhang Y, Li Y, Liu L, Li R, Kong T . Curcumin improves insulin resistance in skeletal muscle of rats. Nutr Metab Cardiovasc Dis. 2010; 21(7):526-33. DOI: 10.1016/j.numecd.2009.11.009. View

12.

Monteiro R, Azevedo I . Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010; 2010. PMC: 2913796. DOI: 10.1155/2010/289645. View

13.

Oh D, Talukdar S, Bae E, Imamura T, Morinaga H, Fan W . GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010; 142(5):687-98. PMC: 2956412. DOI: 10.1016/j.cell.2010.07.041. View

14.

Onat A, Can G, Kaya H, Hergenc G . "Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol. 2010; 4(2):89-98. DOI: 10.1016/j.jacl.2010.02.005. View

15.

Akinkuolie A, Ngwa J, Meigs J, Djousse L . Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials. Clin Nutr. 2011; 30(6):702-7. PMC: 5066815. DOI: 10.1016/j.clnu.2011.08.013. View

16.

Wei M, Jacobson T . Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011; 13(6):474-83. DOI: 10.1007/s11883-011-0210-3. View

17.

Shearer G, Savinova O, Harris W . Fish oil -- how does it reduce plasma triglycerides?. Biochim Biophys Acta. 2011; 1821(5):843-51. PMC: 3563284. DOI: 10.1016/j.bbalip.2011.10.011. View

18.

Shao W, Yu Z, Chiang Y, Yang Y, Chai T, Foltz W . Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One. 2012; 7(1):e28784. PMC: 3253779. DOI: 10.1371/journal.pone.0028784. View

19.

Hardy O, Czech M, Corvera S . What causes the insulin resistance underlying obesity?. Curr Opin Endocrinol Diabetes Obes. 2012; 19(2):81-7. PMC: 4038351. DOI: 10.1097/MED.0b013e3283514e13. View

20.

Im D . Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog Lipid Res. 2012; 51(3):232-7. DOI: 10.1016/j.plipres.2012.02.003. View